UniProt Q96PF2 · PDB · AlphaFold · Substrate: CHKtide · Clone: full length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Brigatinib | 73.9% | 26.1% | 82.96 | 0.513 |
| 2 | Ceritinib | 69.0% | 31.0% | 95.44 | 0.618 |
| 3 | Lorlatinib | 62.1% | 37.9% | 97.24 | 0.694 |
| 4 | Gilteritinib | 39.7% | 60.3% | 88.97 | 0.506 |
| 5 | Tivozanib | 31.1% | 68.9% | 92.42 | 0.673 |
| 6 | Alectinib | 26.6% | 73.4% | 95.49 | 0.651 |
| 7 | Umbralisib | 16.1% | 83.9% | 98.74 | 0.670 |
| 8 | Lazertinib | 15.8% | 84.2% | 97.47 | 0.674 |
| 9 | Defactinib | 12.8% | 87.2% | 92.68 | 0.450 |
| 10 | Selumetinib | 12.6% | 87.4% | 100.00 | 0.640 |
| 11 | Mobocertinib | 12.2% | 87.8% | 97.22 | 0.757 |
| 12 | Pacritinib | 12.1% | 87.9% | 88.64 | 0.452 |
| 13 | Infigratinib | 10.5% | 89.5% | 98.24 | 0.710 |
| 14 | Fostamatinib | 10.3% | 89.7% | 96.74 | 0.613 |
| 15 | Abrocitinib | 9.6% | 90.4% | 99.50 | 0.581 |
| 16 | Remibrutinib | 9.5% | 90.5% | 99.50 | 0.721 |
| 17 | Midostaurin | 9.4% | 90.6% | 78.64 | 0.500 |
| 18 | Gedatolisib | 8.7% | 91.3% | 99.75 | 0.611 |
| 19 | Capmatinib | 8.2% | 91.8% | 99.75 | 0.582 |
| 20 | Leniolisib | 7.9% | 92.1% | 100.00 | 0.604 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 0.03
- Epithelial log2(TPM+1): 0.11
- Fold change: -0.08
- Status: No significant change
Selectivity landscape vs inhibition on TSSK2
Each point is one of the 92 approved drugs; color = inhibition % on TSSK2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…